GlassScriptPhysician profile
Lisa M Grubbs
NPI 1215435912
$1,535.95
in general payments reported to CMS, 2019-2025
21 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $155 · 2023: $182 · 2024: $299 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.17 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $168.97 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $156.98 | 2021-2025 | |
| Abbvie INC. | $151.83 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.29 | 2021-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $90.63 | 2024-2025 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Lilly USA, LLC | $79.55 | 2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $61.94 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $47.61 | 2025 | Voquezna |
| Amgen INC. | $38.10 | 2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $29.79 | 2021 | |
| Rgh Enterprises LLC | $25.55 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.52 | 2021 | |
| Mylan Specialty L.P. | $21.18 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.75 | 2023 | Trintellix |
| Lucid Diagnostics INC. | $18.95 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.74 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Grubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.